XUANZHUBIO-B(02575),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02575 XUANZHUBIO-B

Closed 06-24 16:08:03

15.610

-0.270

-1.70%

High16.520	Low15.410	Vol399.54K
Open15.880	D1 Closing15.880	Amplitude6.99%
Mkt Cap8.09B	Tradable Cap8.09B	Total Shares518.00M
T/O6.33M	T/O Rate0.08%	Tradable Shares517.95M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"XUANZHUBIO-B","latestPrice":15.61,"timestamp":1782288483007,"preClose":15.88,"halted":0,"volume":399540,"delay":0,"changeRate":-0.017002518891687742,"floatShares":517947790,"shares":518000000,"eps":-0.6094461909951158,"marketStatus":"Closed","change":-0.27,"latestTime":"06-24 16:08:03","open":15.88,"high":16.52,"low":15.41,"amount":6329773,"amplitude":0.069899,"askPrice":15.62,"askSize":500,"bidPrice":15.32,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.6036966986272373,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1782351000000},"marketStatusCode":5,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":15.88,"openAndCloseTimeList":[[1782264600000,1782273600000],[1782277200000,1782288000000]],"volumeRatio":0.386282,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02575/tweets","defaultTab":"tweets","newsList":[{"id":"2645604874","title":"Xuanzhu Biopharmaceutical Enrolls First Patient in Anaprazole Sodium Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2645604874","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645604874?lang=en_us&edition=fundamental","pubTime":"2026-06-22 11:47","pubTimestamp":1782100063,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical  enrolled the first patient in the phase 3 study of its stomach-acid drug anaprazole sodium, according to a Sunday filing with the Hong Kong bourse.The firm plans to study the drug as a treatment for Helicobacter pylori, a common bacterial infection linked to ulcers, gastritis, and gastric cancer.The study will enroll 556 adults, and if successful, will help expand the treatment's approval from its current indication of duodenal ulcer.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168313115","title":"Four Hong Kong-listed Companies Launch IPO Processes, Including Medical Robotics Firm, While Able Digital Inks Major Partnership with Alibaba Cloud","url":"https://stock-news.laohu8.com/highlight/detail?id=1168313115","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168313115?lang=en_us&edition=fundamental","pubTime":"2026-06-22 09:07","pubTimestamp":1782090474,"startTime":"0","endTime":"0","summary":"Several significant corporate developments have been announced in the Hong Kong market, covering new share offerings, strategic partnerships, and investment activities. Key Corporate Actions The...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2213484517.USD","LU1960683339.HKD","LU0880133367.SGD","BK1610","02687","BK1554","BK1228","BK1207","06715","BK1216","LU0359202008.SGD","LU1807302812.USD","06915","BK1594","BK1151","01250","LU0067412154.USD","00697","06887","02697","002352","03750","LU1008478684.HKD","LU1152091754.HKD","LU1993786604.SGD","LU0359201612.USD","01798","02657","06936","02558","BK1558","BK1191","BK1154","02575","LU1152091168.USD","LU1023057109.AUD","LU0359201885.HKD","SCGEY","03952","BK1560","300750","BK1235","BK1116"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122383034","title":"Xuanzhu Bio-B Initiates Phase III Trial for H. Pylori Eradication with New Anaprazole Sodium Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=1122383034","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122383034?lang=en_us&edition=fundamental","pubTime":"2026-06-21 18:14","pubTimestamp":1782036871,"startTime":"0","endTime":"0","summary":"Xuanzhu Bio-B (02575) has announced that its self-developed innovative drug, Anaprazole Sodium Enteric-coated Tablets (brand name: Anjiuwei®), has successfully enrolled the first patient into a Phase...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","III","BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645628097","title":"Xuanzhu Biopharma enrolls first patient in Phase III trial of anaprazole sodium for H. pylori eradication","url":"https://stock-news.laohu8.com/highlight/detail?id=2645628097","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645628097?lang=en_us&edition=fundamental","pubTime":"2026-06-21 18:05","pubTimestamp":1782036350,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical enrolled the first patient in a Phase III trial of anaprazole sodium in Helicobacter pylori eradication therapy.Trial results have not been presented; the study will assess whether the regimen can clear infection safely versus an esomeprazole-based comparator.The study targets 556 adults across multiple centers with a 14-day treatment course.Anaprazole sodium is already marketed in China for duodenal ulcer; success could broaden its label and support faster commercial uptake.The company cited China’s H. pylori drug market at RMB 5.5 billion in 2024, projecting RMB 6.8 billion in 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to genera","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260621:nNDL8bPT69:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","00460","BK1600","BK1515","BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188910815","title":"XUANZHUBIO-B Announces Election of Employee Representative Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1188910815","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188910815?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:28","pubTimestamp":1781778509,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) has issued a formal announcement regarding a board appointment.The company's employee representative congress convened on June 18, 2026.During the meeting, Ms. Yue Xin was...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153865036","title":"Xuanzhu Biopharmaceutical Tightens Governance Framework in Revised Articles; Confirms 9-Member Board and HK$517.95 Million Share Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=1153865036","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153865036?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:25","pubTimestamp":1781778348,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharmaceutical) has released its revised Articles of Association (effective June 2026), detailing updated corporate governance structures, capital...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644702139","title":"Xuanzhu Biopharmaceutical files director list with Hong Kong Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2644702139","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644702139?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:25","pubTimestamp":1781778311,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical filed an updated list of directors with the Hong Kong Stock Exchange on June 18, 2026.Xu Yanjun remains chairperson of the board, also serving as general manager.The board comprises executive, non-executive, employee representative, and independent non-executive directors; key committee chairs are held by independent directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDLbTRqvN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","02575","BK1191","BK1515","BK1593","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644611702","title":"Xuanzhu Biopharma names Yue Xin employee representative director after election","url":"https://stock-news.laohu8.com/highlight/detail?id=2644611702","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644611702?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:21","pubTimestamp":1781778080,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical named Yue Xin as employee representative director, effective June 18, 2026.Yue replaces an executive director seat as the board shifts its composition.Li Jia Kui’s resignation as executive director takes effect immediately on Yue’s appointment.Yue served as a company supervisor from November 2021 to June 2026.She joined the group in 2019, rising from administrative assistant to head of administration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDLbVnXtt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","00460","02575","BK1600","BK1515","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147854758","title":"Xuanzhu Bio Converts 357.25 Million Unlisted Shares to H Shares, Expanding Total Issued Capital to 517.95 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1147854758","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147854758?lang=en_us&edition=fundamental","pubTime":"2026-06-04 19:03","pubTimestamp":1780571015,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Bio) disclosed its Monthly Return for Equity Issuer for the period ended 31 May 2026, highlighting a substantial restructuring of its share structure...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173805012","title":"XUANZHUBIO-B Shares Surge as Three Key Products Advance to Commercial Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1173805012","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173805012?lang=en_us&edition=fundamental","pubTime":"2026-06-04 14:50","pubTimestamp":1780555828,"startTime":"0","endTime":"0","summary":"Shares of XUANZHUBIO-B (02575) rose more than 5% in trading. At the time of writing, the stock was up 5.17% to HK$17.29, with a turnover of HK$46.84 million. Key Drivers Behind the Move A recent...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191","VXUS","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123331571","title":"Xuanzhu Biopharma to Seek Shareholder Nod on 2025 Reports, Profit Distribution and Board Mandates at 18 June 2026 AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=1123331571","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123331571?lang=en_us&edition=fundamental","pubTime":"2026-05-27 17:04","pubTimestamp":1779872659,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharma) has issued the proxy form and agenda for its annual general meeting scheduled for 10:30 a.m. on Thursday, 18 June 2026 at the Jing Tai Lan...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638080355","title":"Xuanzhu Biopharmaceutical announces annual general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2638080355","media":"Reuters","labels":["conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638080355?lang=en_us&edition=fundamental","pubTime":"2026-05-27 16:52","pubTimestamp":1779871976,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical will hold its 2025 annual general meeting in Beijing on June 18, 2026.Shareholders will vote on the 2025 annual report package, including the board report, supervisory committee report, audited consolidated financial statements.A profit distribution plan will be tabled, with the board not recommending a final dividend for 2025.Items include a directors’ remuneration plan, reappointment of Ernst & Young as 2026 auditor, estimated audit fee RMB 2 million.Special resolutions cover mandates to repurchase up to 10% of issued H shares, issue up to 20%, abolish the supervisory committee, amend the articles.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original conten","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL5RwMrH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575","BK1515","BK1600","00460","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638518902","title":"Xuanzhu Biopharmaceutical seeks bylaw changes to scrap supervisory committee, shift oversight to audit committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2638518902","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638518902?lang=en_us&edition=fundamental","pubTime":"2026-05-26 17:46","pubTimestamp":1779788807,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical proposed bylaw amendments to abolish its supervisory committee, shifting oversight to an audit committee.Board structure would add an employee representative director as a non-executive, elected via an employee representative meeting.Executive director Li Jia Kui’s resignation would take effect upon that appointment, filling the vacancy created by his departure.Post-change board would comprise 2 executive directors, 4 non-executive directors, 3 independent non-executive directors.Shareholders will vote on the amendments at the June 18, 2026 AGM via special resolution.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brie","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL62ZvLc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1191","02575","BK1600","BK1515","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100532115","title":"Registration Open for \"Zhihui Financial 2026 Summer Roadshow Conference\"","url":"https://stock-news.laohu8.com/highlight/detail?id=1100532115","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100532115?lang=en_us&edition=fundamental","pubTime":"2026-05-18 10:47","pubTimestamp":1779072449,"startTime":"0","endTime":"0","summary":"In the first half of 2026, the Hong Kong capital market is experiencing a long-awaited period of heightened activity. Since the second quarter, the Hong Kong market has been on a sustained recovery...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1224709979.USD","02623","02526","BK1110","00400","LU0572939691.SGD","LU0588546209.SGD","LU1813983027.USD","LU0359201885.HKD","02726","LU0314109678.HKD","01378","02228","BK1198","BK1592","BK1258","01396","LU1303224171.USD","BK1132","02650","01907","02889","BK1238","BK1583","BK1229","06051","BK1539","BK1183","02575","LU1166156734.SGD","LU0307460666.USD","BK1162","LU0702159699.USD","BK1100","BK1541","LU0345781412.USD","SG9999014674.SGD","02706","BK1171","LU0287142896.SGD","BK1225","LU2039709279.SGD","BK1147","VXUS","LU0359201612.USD","BK1149","BK1129","BK1155","09696","LU1770034418.SGD","BK1116","BK1144","BK1109","02675","00826","00650","LU0572940350.SGD","03858","LU1023057109.AUD","BK4588","BK1190","02652","BK1163","02655","LU1251922891.USD","LU0630314457.HKD","06636","06090","08299","BK1500","06651","02685","LU0737861699.HKD","BK4585","BK1613","LU0264606111.USD","01333","BK1249","06938","02411","01021","HK0001040143.USD","02729","BK1191","HK0001040168.HKD","BK1594","00305","BK1175","LU0469268626.HKD","BK1117","BK1207","06682","01300","SG9999001093.SGD","BK1141","02659","BK1230","03317","BK1617","BK1161","01384","LU1719994722.HKD","BK1142","BK1205","BK1574","00290","LU0359202008.SGD","BK1240","BK1506","02670","LU0173614495.USD","02142","02565","00363","LU1328277881.USD","03881","BK1578","LU0345780950.USD","BK1169"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175245965","title":"Xuanzhu Biopharma Converts 357.25 Million Unlisted Shares into H Shares, Lifting Issued Share Base by 68.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=1175245965","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175245965?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:02","pubTimestamp":1778583763,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharma) has completed the conversion of 357.25 million unlisted shares into the same number of H shares, according to its Next Day Disclosure Return...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112216216","title":"Xuanzhu Biopharmaceutical Completes H-Share Full Circulation, Converts 357.25 Million Unlisted Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1112216216","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112216216?lang=en_us&edition=fundamental","pubTime":"2026-05-12 17:03","pubTimestamp":1778576591,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. announced on 12 May 2026 that it has finalised its H-share full-circulation programme, converting 357.25 million unlisted domestic shares into H shares. The newly...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126727555","title":"XUANZHUBIO-B Completes Full Circulation of H Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1126727555","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126727555?lang=en_us&edition=fundamental","pubTime":"2026-05-12 16:34","pubTimestamp":1778574869,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) has announced that on May 12, 2026, a total of 357 million non-tradable shares have been converted. These converted H shares will commence trading on the Stock Exchange starting at 9:00 a.m. on May 13, 2026.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634296712","title":"Xuanzhu Biopharmaceutical converts 357,245,794 unlisted shares into H shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2634296712","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634296712?lang=en_us&edition=fundamental","pubTime":"2026-05-12 16:31","pubTimestamp":1778574709,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical completed conversion of 357,245,794 unlisted shares into H shares on May 12.Converted H shares start trading in Hong Kong at 9:00 a.m. on May 13.H-share count rises to 517,947,790 from 160,701,996; unlisted shares drop to zero.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL6srlSn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1593","BK1600","BK1515","BK1191","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633972317","title":"Here's Why We're Not Too Worried About Xuanzhu Biopharmaceutical's (HKG:2575) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2633972317","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633972317?lang=en_us&edition=fundamental","pubTime":"2026-05-06 07:15","pubTimestamp":1778022949,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2575/xuanzhu-biopharmaceutical-shares/news/heres-why-were-not-too-worried-about-xuanzhu-biopharmaceutic","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2575/xuanzhu-biopharmaceutical-shares/news/heres-why-were-not-too-worried-about-xuanzhu-biopharmaceutic","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196960560","title":"XUANZHUBIO-B Accelerates Domestic Commercialization and Secures Major Overseas Licensing Deal, Broadening Growth Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=1196960560","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196960560?lang=en_us&edition=fundamental","pubTime":"2026-04-28 08:27","pubTimestamp":1777336035,"startTime":"0","endTime":"0","summary":"Revenue surged by over 70% year-on-year, signaling imminent commercialization breakthroughs for its three key drivers... In 2025, XUANZHUBIO-B successfully entered a phase of full-scale...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xuanzhubio.com","stockEarnings":[{"period":"1week","weight":-0.0457},{"period":"1month","weight":-0.1128},{"period":"3month","weight":-0.5623},{"period":"6month","weight":-0.7746},{"period":"1year","weight":0.369},{"period":"ytd","weight":-0.7748}],"compareEarnings":[{"period":"1week","weight":-0.0473},{"period":"1month","weight":-0.0886},{"period":"3month","weight":-0.0789},{"period":"6month","weight":-0.0962},{"period":"1year","weight":-0.0149},{"period":"ytd","weight":-0.0895}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Xuanzhu Biopharmaceutical Co Ltd is a China-based company principally engaged in biopharmaceutical business. The Company is primarily engaged in business of research and development, manufacturing and commercialization of innovative drugs, focusing on a number of therapeutic areas such as digestion, oncology and non-alcoholic steatohepatitis (NASH). The Company’s main products include KBP-3571, XZP-3287 and XZP-3621. The Company mainly conducts its businesses in the domestic market.","exchange":"SEHK","name":"XUANZHUBIO-B","nameEN":"XUANZHUBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"XUANZHUBIO-B(02575),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest XUANZHUBIO-B(02575) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"XUANZHUBIO-B,02575,XUANZHUBIO-B股票,XUANZHUBIO-B股票老虎,XUANZHUBIO-B股票老虎国际,XUANZHUBIO-B行情,XUANZHUBIO-B股票行情,XUANZHUBIO-B股价,XUANZHUBIO-B股市,XUANZHUBIO-B股票价格,XUANZHUBIO-B股票交易,XUANZHUBIO-B股票购买,XUANZHUBIO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"XUANZHUBIO-B(02575),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest XUANZHUBIO-B(02575) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}